TOKYO (Reuters) - Miraca Holdings <4544.T>, Japan's top diagnostics and laboratory testing service provider, will buy a unit of U.S.-based Caris Life Sciences for $725 million, joining a rush by ...
MIRACA HOLDINGS INC ORD by Miraca Holdings, Inc. issues dividends to shareholders from excess cash MIRACA HOLDINGS INC ORD by Miraca Holdings, Inc. generates. Most companies pay dividends on a ...
IRVING, Texas--(BUSINESS WIRE)--Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring ...
IRVING, Texas--(BUSINESS WIRE)--Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, has launched the EoGenius™ test which helps diagnose and monitor patients with ...
Miraca reveals earnings for the most recent quarter on February 9. Analysts are expecting earnings per share of ¥12.31. Go here to follow Miraca stock price in real-time ahead of earnings. Miraca will ...
Miraca Holdings is taking over the anatomic pathology business run by Caris Diagnostics (CDx), a unit of Caris Life Sciences (CLS), and its subsidiaries and affiliates. The transaction will be valued ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
TOKYO—Little-known Japanese drug maker Miraca Holdings Inc. agreed to buy the anatomic-pathology business of Texas-based Caris Life Sciences Inc. for $725 million, the latest sign that small Japanese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results